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INTRODUCTION
Smith-Lemli-Opitz syndrome (SLOS, OMIM 270400) is
an autosomal recessive disorder caused by mutations of 7-
dehydrocholesterol reductase gene (DHCR7) (1-4). DHCR7
deficiency impairs cholesterol production, resulting in accu-
mulation of precursor sterols, 7-dehydrocholesterol (7DHC)
(5). The estimated incidence of SLOS is 1 in 20,000-40,000
births in the Caucasian population (6-8). On the other hand,
the incidence is low in African and Asian populations (9-11)
and only one case has been reported in Korea thus far (12).
Patients with SLOS show a wide variability of congenital
anomalies, including dysmorphic facies, microcephaly, cleft
palate, syndactyly of toes 2 and 3, visceral malformations,
congenital heart defects, and ambiguous genitalia (7). Fail-
ure to thrive, behavior problems, and mental retardation are
hallmarks of the disorder. The spectrum of phenotype is vari-
able, from early embryonal non-viability to patients with min-
imal physical abnormalities and normal intelligence or mini-
mal intellectual impairment. Liver disease has been report-
ed infrequently in SLOS (13). We found a case of SLOS who
presented with neonatal cholestasis and identified a novel
mutation of the DHCR7 gene. 
CASE REPORT
Patient
A boy, weighing 1,780 g at birth, was born in a breech pre-
sentation by cessarian section to a 27-yr-old primigravida at
36 weeks of gestation. An obstetrical ultrasound evaluation
had shown oligohydramnios and ambiguous genitalia. Apgar
scores were 2 at one minute and 5 at five minutes. He was
intubated for poor respiratory function and positive airway
pressure was administered. Physical examination disclosed
microcephaly, micrognathia, a small nose with anteverted
nares, ambiguous genitalia, cleft palate, simian line, and bilat-
eral syndactyly of the second and third toes. Chromosomal
analysis showed a 46,XY karyotype. Echocardiography re-
vealed large patent ductus arteriosus (PDA) and atrial septal
defect. PDA ligation was done because of progressive heart
failure. At 1 month of age, he exhibited feeding intolerance.
Abdominal ultrasonography and upper GI series showed hyper-
trophic pyloric stenosis, and pyloromyotomy was done. 
Persistent jaundice and failure to thrive were noted at 4
months of age. The infant weighed 2,900 g. Physical exam-
ination showed ptosis and hypotonia. The hard liver was pal-
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A Novel DHCR7 Mutation in a Smith-Lemli-Opitz Syndrome Infant
Presenting with Neonatal Cholestasis
Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive malformation syn-
drome caused by a defect in cholesterol biosynthesis. The incidence is very low in
Asians and only one case has been reported in Korea thus far. Recently, we found
an infant with neonatal cholestasis. He had microcephaly, ambiguous genitalia, cleft
palate, syndactyly of toes, patent ductus arteriosus and hypertrophic pyloric steno-
sis. The serum cholesterol was decreased and serum 7-dehydrocholesterol was
markedly elevated. Genetic analysis of the DHCR7 gene identified a novel missense
mutation (Pro227Ser) as well as a known mutation (Gly303Arg) previously identi-
fied in a Japanese patient with SLOS. Although rare in Korea, SLOS should be con-
sidered in the differential diagnosis of neonatal cholestasis, especially in patients
with multiple congenital anomalies and low serum cholesterol levels.
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Accepted : 18 August 2008pable 3 cm below the costal margin. Blood chemistry showed
a total bilirubin of 8.6 mg/dL direct bilirubin of 4.7 mg/dL,
aspartate aminotransferase of 176 IU/L, alanine aminotrans-
ferase of 86 IU/L, and GGT of 13 IU/L. Prothrombin time
was prolonged (INR 1.85). Leukocytosis (white blood cell
count 20,000/mL) and anemia (hemoglobin 8.8 g/dL) were
noted. Serology for hepatitis A, B, and C, toxoplasma, rubel-
la, cytomegalovirus, herpes simplex was negative. Screening
tests for metabolic disorders were negative. The serum choles-
terol level was reduced (21 mg/dL) and serum 7DHC level
by gas chromatography-mass spectrometry was markedly ele-
vated (567 mg/mL). 
Ultrasonography of the abdomen showed hepatomegaly
with increased echogenicity and bilateral cystic renal disease.
A liver biopsy revealed the ballooning or feathery degenera-
tion and macro-vesicular fatty change of hepatocytes, peripor-
tal fibrosis, and ductular proliferation associated with neu-
trophilic infiltration (Fig. 1). He developed fever, and broad-
spectrum antibiotics were given. Dietary cholesterol (egg yolk)
and fat soluble vitamins were supplemented. Generalized tonic
seizure with apnea developed and electroencephalography
revealed a partial seizure. The disease severity was scored as
reported previously (14). The clinical severity score was 55
and he was classified into the severe phenotype.
Genetic analysis
Genomic DNA was extracted from whole blood, in accor-
dance with standard methods. Informed consent was obtained
from the parents. Mutation analysis of DHCR7 was performed
using PCR amplification and direct sequencing of DHCR7
coding exons and their intron/exon boundaries as previously
described (12). 
DISCUSSION
Two missense variations were identified in the patient. One
was a C to T transition at nucleotide 679 (c.679C>T) in exon
7, resulting in a Pro to Ser substitution at the 227th residue
(Pro227Ser; Fig. 2A). The other was a G to A transition at
nucleotide 907 (c.907G>A) in exon 8, resulting in a Gly to
Arg substitution at the 303rd residue (Gly303Arg; Fig. 2A).
Both variations were inherited from the patient’s mother and
father, respectively. While Gly303Arg has been reported in
a Japanese patient with SLOS (15), Pro227Ser variation has
not been reported previously and it alters conserved residue
among different species (Fig. 2B).
The frequency of hepatic manifestation in SLOS was report-
ed to be low, ranged from 2.5% to 16% (9, 13, 15). Although
cholestatic liver disease and isolated hypertransaminasemia
were reported in SLOS, there are few studies investigating
the histological abnormalities of the liver. In the present study,
histologic findings showed septal fibrosis, ductular prolifer-
ation, and ballooning degeneration of hepatocytes, which are
consistent with those of Rossi et al. (13). Since bile acids are
synthesized from cholesterol, cholestasis may be caused by im-
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Fig. 1. Percutaneous liver biopsy exhibited ballooning or feathery
degeneration and macrovesicular fat droplets in lobular hepato-
cytes and periportal fibrosis and ductular proliferation in a portal
space.  
A
B
H. sapiens DHCR7 (NP_001351.2) EF N R P IG
M. musculus Dhcr7 (NP_031882.1) EF N R P IG
G. gallus Dhcr7 (XP_420914.1) EF N R P IG
D. rerio dhcr7 (NP_958487.1) EF N R P IG
B. taurus DHCR7 (NP_001014927.1) EF N R P IG
X. tropicalis dhcr7 (NP_989235.1) EF N R P IG
R. norvegicus Dhcr7 (NP_071784.1) EF N R P IG
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Fig. 2. (A) Direct sequencing of the DHCR7 gene. A novel mis-
sense mutation (c.679C>T; Pro227Ser) was identified in the patient
and his mother (filled arrow) and a known mutation was found in
the patient and his father (open arrow). (B) The Pro227Ser muta-
tion was evolutionary conserved residue among different species.
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein)paired bile acid synthesis due to a severe deficiency of DHCR.
Severe cholestasis in SLOS was reported to be associated with
severe phenotypes, while isolated hypertransaminasemia was
associated with milder phenotypes (16). Our patient presented
with severe cholestasis and severe phenotype. Serum GGT
levels were normal in our case in spite of severe cholestasis.
Normal GGT with neonatal cholestasis is also shown in pro-
gressive familial intrahepatic cholestasis 1 and 2, ARC syn-
drome, and inborn errors of bile acid synthesis. 
To date more than 120 mutations have been identified (17).
The missense mutations account for 87% of the total muta-
tions. Fifty percent of the missense mutations are located in
one of the nine predicted transmembrane domains. The p.-
Gly303Arg mutation was previously reported in Japanese
SLOS patients and it is located in the seventh transmembrane
domain, which represent a highly conserved sterol-sensing
domain (14). The p.Pro227Ser mutation is located in the
second cytoplasmic loop, and previously described mutations
in this loop are p.Gln224Lys and p. Arg228Trp (18). Three
mutations including IVS-1G→C, p.Thr93Met, and p.Va-
l326Leu account for 50% of the spectrum of mutations in
Caucasian patients (19). On the other hand, p.Arg325Gln
is the most common mutation in Japanese SLOS patients
(14). The previously reported case of SLOS in Korea harbored
compound heterozygous mutations including p.Arg352Trp
and p.Lys376ArgfsX37 (12). DHCR7 mutation patterns in
Asian patients are different from those observed among Cau-
casians.
The genotype-phenotype analysis showed that most homo-
zygotes for frameshift and nonsense mutations had the severe
phenotypes (20). However, Yu et al. (17) showed that there
was great variation in severity in patients that had the same
type of mutations. 
In summary, we found a case of SLOS with mutations of
the DHCR7 gene and neonatal cholestasis. SLOS should be
considered in the differential diagnosis of neonatal cholesta-
sis, especially in patients with multiple congenital anoma-
lies and low serum cholesterol levels.
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